Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July.
What The Study Did: This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of white patients did.
Men over 60 with low-risk prostate cancer could spend ten years with no active treatment, have a better sex life as a result, yet still be very unlikely to die from the disease, new research has found.
Obese patients with a form of advanced prostate cancer survive longer than overweight and normal weight patients, new research has found.
A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.
Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half. The results are presented today at the European Association of Urology Congress.
Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyse CT scans in just seconds.
Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at stages where the disease has spread to the bones. However, new research has found that anti-androgen treatment can actually facilitate prostate cancer cells to adapt and grow in the bone tumour microenvironment model, which has been developed by QUT biomedical scientists led by Dr Nathalie Bock.
A new prognostic tool helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.
New research has shown myelosuppressive chemotherapy destabilises gut microbiome in patients with solid organ cancers. The study from SAHMRI and Flinders University assessed the gut health of men and women who underwent conventional chemotherapy on cancers, such as breast and lung cancer, without exposure to antibiotics.